Minireview: Remdesivir, A Prominent Nucleotide/Nucleoside Antiviral Drug. (14th September 2022)

• Record Type: Journal Article
• Authors: Rammohan, Aluru; Zyryanov, Grigory V.
• Is Part Of: Polycyclic aromatic compounds. Volume 42:Number 8(2022)
• Page Start: 5824
• Page End: 5831
• Publication Date: 2022-09-14
• Subjects: Antiviral drug -- nucleotide analogue -- remdesivir -- synthesis; Polycyclic aromatic compounds -- Periodicals; 547
• DOI: 10.1080/10406638.2021.1947331
• Languages: English
• ISSNs: 1040-6638

Abstract

Abstract: Nucleotide analogues are the divergent scaffolds that are reliable potential therapeutic drugs to treat the wide range of diseases including viral infections. For instance, Remdesivir is a biologically important nucleotide analogue prodrug that can act as a key drug target for the diseases Ebola and COVID-19. Remdesivir is a structurally chiral aryloxy-phosphoramidate prodrug as it is metabolized into nucleoside triphosphate (active drug form) inside the cell through sequential reactions by ester mediated-hydrolysis. Thus, the current minireview focuses on the earlier reported synthetic approaches of key fragments of remdesivir and their developments to attain the scale-up yields of the drug for clinical/commercial applies. Further, this review serves as a template for the design and development of other complex organic molecules.